Thank you for Subscribing to Life Science Review Weekly Brief
Vineti and Autolomous has formed a strategic agreement to provide end-to-end supply chain management solutions.
FREMONT, CA: “Autolomous is now building strategic value-add collaborations across the cell and gene therapy industry to provide solutions to critical needs within value chains. This will result in a holistic platform that specifically targets critical ecosystem partners, including healthcare providers, such as the UKs NHS, personalized therapy management platform providers including Vineti and those involved in the manufacturing component of supply chains, such as Autolomous,” states Alexander Seyf, CEO and Co-founder, Autolomous LTD. “We have selected to collaborate with Vineti to provide a unified single digital solution that can be used from the collection of patient starting material, manufacturing, through to the delivery of therapies. The seamless integration between Autolomous and VInetis solutions will ensure scalability when cell and gene therapies become standard of care, and involve a plethora of supply chain partners and patient samples.” Autolomous LTD, a world leader in essential production management systems for cell and gene treatments, and Vineti, a provider of market-leading digital enterprise platforms for cell and gene therapy supply chains, form a non-exclusive cooperation partnership.
“Partnering with Autolomous will allow Vineti to expand its provision across the CGT value chain. The integration of both organizations technologies will give Vineti additional tools to satisfy the rising procurement and delivery demands of the CGT sector,” comments Amy DuRoss, CEO and Co-founder, Vineti Inc. “Both companies are specialized within the heart of the CGT value chain and have delivered outputs that have made considerable and tangible cross-sector enhancements. The collaboration between Autolomous and Vineti will enable the provision of solutions required by the industry as it reaches a much larger scale.”
Autolomous' crucial manufacturing management systems will be integrated with Vinetis' Personalized Therapy Management® (PTM) platform as part of the agreement. This will enable both parties to establish a fully integrated end-to-end cell and gene therapy (CGT) delivery pathway, including crucial inbound and outbound manufacturing value processes. As a result, visibility and dynamic information flow between and among stakeholders throughout the cell & gene therapy value chain will rise. This enables them to respond to unforeseeable variables associated with biological process operations. Additionally, by boosting transparency, compliance, and auditability, the integration of technologies enables production to scale rapidly while also offering considerable time and resource savings through efficiency advantages.